Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.

Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, Hwang PH, Hoyte EG, Garcia MA, Nadeau KC.

J Allergy Clin Immunol. 2012 Jul;130(1):215-24.e7. doi: 10.1016/j.jaci.2012.04.021. Epub 2012 Jun 5. Erratum in: J Allergy Clin Immunol. 2012 Nov;130(5):1224.

2.

Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.

Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, Pitkin L, Pilette C, Nouri-Aria K, Durham SR.

Clin Exp Allergy. 2010 Apr;40(4):598-606. doi: 10.1111/j.1365-2222.2010.03462.x. Epub 2010 Feb 22.

PMID:
20184605
3.

Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation.

Suárez-Fueyo A, Ramos T, Galán A, Jimeno L, Wurtzen PA, Marin A, de Frutos C, Blanco C, Carrera AC, Barber D, Varona R.

J Allergy Clin Immunol. 2014 Jan;133(1):130-8.e1-2. doi: 10.1016/j.jaci.2013.09.043. Epub 2013 Nov 28.

PMID:
24290282
4.

Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.

Bonvalet M, Moussu H, Wambre E, Ricarte C, Horiot S, Rimaniol AC, Kwok WW, Horak F, de Beaumont O, Baron-Bodo V, Moingeon P.

Clin Exp Allergy. 2012 Dec;42(12):1745-55. doi: 10.1111/cea.12015.

PMID:
23181790
5.

Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.

Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, Barlan IB.

Respir Med. 2013 Sep;107(9):1322-9. doi: 10.1016/j.rmed.2013.06.021. Epub 2013 Jul 23.

6.

Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects.

Szépfalusi Z, Bannert C, Ronceray L, Mayer E, Hassler M, Wissmann E, Dehlink E, Gruber S, Graf A, Lupinek C, Valenta R, Eiwegger T, Urbanek R.

Pediatr Allergy Immunol. 2014 Dec;25(8):788-95. doi: 10.1111/pai.12310.

PMID:
25406682
8.
9.

Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis.

Smith H, White P, Annila I, Poole J, Andre C, Frew A.

J Allergy Clin Immunol. 2004 Oct;114(4):831-7.

PMID:
15480323
10.

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.

Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S.

J Allergy Clin Immunol. 2006 Apr;117(4):802-9.

PMID:
16630937
11.

Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy.

Nieminen K, Valovirta E, Savolainen J.

Pediatr Allergy Immunol. 2010 Feb;21(1 Pt 2):e174-84. doi: 10.1111/j.1399-3038.2009.00920.x. Epub 2009 Jun 29.

PMID:
19566585
12.

Immunotherapy is allergen-specific: a double-blind trial of mite or timothy extract in mite and grass dual-allergic patients.

Dreborg S, Lee TH, Kay AB, Durham SR.

Int Arch Allergy Immunol. 2012;158(1):63-70. doi: 10.1159/000330649. Epub 2011 Dec 29.

PMID:
22212720
13.

Innate and lymphocytic response of birch-allergic patients before and after sublingual immunotherapy.

Guida G, Boita M, Scirelli T, Bommarito L, Heffler E, Badiu I, Bellone G, Mietta S, Mistrello G, Rolla G.

Allergy Asthma Proc. 2012 Sep-Oct;33(5):411-5. doi: 10.2500/aap.2012.33.3588. Epub 2012 Jul 3.

PMID:
22762741
14.

Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.

Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T, Braun W.

Allergy. 2004 May;59(5):498-504.

15.

Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.

Roberts G, Hurley C, Turcanu V, Lack G.

J Allergy Clin Immunol. 2006 Feb;117(2):263-8.

PMID:
16461125
16.

House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.

O'Hehir RE, Gardner LM, de Leon MP, Hales BJ, Biondo M, Douglass JA, Rolland JM, Sandrini A.

Am J Respir Crit Care Med. 2009 Nov 15;180(10):936-47. doi: 10.1164/rccm.200905-0686OC. Epub 2009 Aug 20.

PMID:
19696440
17.

A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.

Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV, Hammermann J, Leupold W, Bartels P, Gruebl A, Bauer CP, Schnitker J, Wahn U, Niggemann B.

Allergy. 2004 Dec;59(12):1285-93.

18.

Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.

Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS.

J Allergy Clin Immunol. 2009 Jul;124(1):150-156.e1-5. doi: 10.1016/j.jaci.2009.04.037. Epub 2009 Jun 11.

PMID:
19523672
19.

Shorter dosing intervals of sublingual immunotherapy lead to more efficacious treatment in a mouse model of allergic inflammation.

Rask C, Brimnes J, Lund K.

Scand J Immunol. 2010 Jun;71(6):403-12. doi: 10.1111/j.1365-3083.2010.02394.x.

20.

Sublingual immunotherapy for allergic rhinitis.

Wilson DR, Torres LI, Durham SR.

Cochrane Database Syst Rev. 2003;(2):CD002893. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD002893.

PMID:
12804442

Supplemental Content

Support Center